_
Cutting corners in Research and Development
Haim Handwerker, "Cutting corners in R&D" (13 December 2004, Haaretz Daily)
Leading text: "A few weeks ago Ranan Lachman organized a symposium in the framework of the Israeli Business Forum of New York, inviting a number of Israeli professionals residing in the U.S. to participate. Lachman's goal was to present the work experience opposite Israeli biotech, to learn the lessons and examine ways to promote this industry.
Yael Cohen, who works as a scientist at Merck, told the participants that she had discovered an entrepreneurial atmosphere in Israel." The research is on a high level," says Cohen. "From the perspective of the number of scientists in the life sciences per capita, and the number of famous scientists, Israel is in one of the top spots in the world. Biotechnology receives priority from the government (after high-tech), but due to insufficient infrastructure and a lack of clinical knowledge, it is difficult for Israeli companies to bridge the gap between their advanced research knowledge and the development of drugs and their introduction to the market. Some 70 percent of the companies are young and very small (up to 10 workers). Only 25 percent of the companies have been around for over 7 years, and just over 30 percent are less than 2 years old. In a situation like this it is hard to push forward..." [FullText]
Leading text: "A few weeks ago Ranan Lachman organized a symposium in the framework of the Israeli Business Forum of New York, inviting a number of Israeli professionals residing in the U.S. to participate. Lachman's goal was to present the work experience opposite Israeli biotech, to learn the lessons and examine ways to promote this industry.
Yael Cohen, who works as a scientist at Merck, told the participants that she had discovered an entrepreneurial atmosphere in Israel." The research is on a high level," says Cohen. "From the perspective of the number of scientists in the life sciences per capita, and the number of famous scientists, Israel is in one of the top spots in the world. Biotechnology receives priority from the government (after high-tech), but due to insufficient infrastructure and a lack of clinical knowledge, it is difficult for Israeli companies to bridge the gap between their advanced research knowledge and the development of drugs and their introduction to the market. Some 70 percent of the companies are young and very small (up to 10 workers). Only 25 percent of the companies have been around for over 7 years, and just over 30 percent are less than 2 years old. In a situation like this it is hard to push forward..." [FullText]
posted by Dr.Koudinov @ 24.12.04
0 Comments:
Post a Comment
<< Home